C12Y 304/21061
Kexin , i.e. proprotein convertase subtilisin/kexin type 9
Official title: Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
C12Y304/21061 (Kexin , i.e. proprotein convertase subtilisin/kexin type 9) appears on 59 US grants and 150 published applications in this corpus.
Search patents in C12Y- Granted patents
- 59
- Published applications
- 150
- Assignees
- 94
- Inventors
- 345
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 1 | 0 |
| 2010 | 1 | 2 |
| 2011 | 1 | 5 |
| 2012 | 1 | 4 |
| 2013 | 3 | 8 |
| 2014 | 1 | 2 |
| 2015 | 4 | 5 |
| 2016 | 4 | 6 |
| 2017 | 4 | 8 |
| 2018 | 9 | 11 |
| 2019 | 3 | 10 |
| 2020 | 2 | 6 |
| 2021 | 6 | 14 |
| 2022 | 3 | 5 |
| 2023 | 5 | 16 |
| 2024 | 5 | 11 |
| 2025 | 4 | 15 |
| 2026 | 2 | 21 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Fusion polypeptides24 Feb 2026US 12,559,759 B2Danisco US Inc.
- Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use3 Feb 2026US 12,540,323 B2Suzhou Ribo Life Science Co., Ltd.
- Oral delivery of antisense conjugates targeting PCSK96 May 2025US 12,291,708 B2CiVi Biopharma, Inc.
- Anti-PCSK9 antibodies8 Apr 2025US 12,269,897 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for delivery of biomacromolecule agents25 Mar 2025US 12,257,352 B2The Regents of the University of Michigan
- Sirna molecule for regulating pcsk9 gene activity1 Oct 2026US 2026/0297585 A1Rona Bioscience, Limited
- Vector production24 Sep 2026US 2026/0286391 A1Fondazione Telethon Ets
- Rnai formulation for inhibiting pcsk9 gene expression and use thereof20 Aug 2026US 2026/0242798 A1Mabwell (Shanghai) Bioscience Co., Ltd.
- Sirnas for simultaneously inhibiting expression of two target genes, drug and use thereof6 Aug 2026US 2026/0226469 A1BeBetter Med Inc.
- Methods for reducing the risk of major adverse cardiovascular events in primary prevention subjects6 Aug 2026US 2026/0226473 A1Novartis AG
Most cited
By later US patents
- High affinity human antibodies to PCSK9143US 8,062,640 B2Regeneron Pharmaceuticals, Inc. · 2011
- Methods for increasing efficacy of lipid formulated siRNA103US 9,051,567 B2Tekmira Pharmaceuticals Corporation · 2015
- Polynucleotides encoding novel PCSK9 variants94US 7,572,618 B2Bristol-Myers Squibb Company · 2009
- High affinity human antibodies to PCSK975US 8,501,184 B2Regeneron Pharmaceuticals, Inc. · 2013
- Inhibition of PCSK9 through RNAi48US 9,493,774 B2RXi Pharmaceuticals Corporation · 2016